Monoclonal Antibody to Glutamate Receptor, Ionotropic, N-Methyl-D-Aspartate 2D (GRIN2D)
| Code | Size | Price |
|---|
| MAE809Hu25-20ul | 20uL | £91.00 |
Quantity:
| MAE809Hu25-100ul | 100ul | £172.00 |
Quantity:
| MAE809Hu25-200ul | 200ul | £232.00 |
Quantity:
| MAE809Hu25-1ml | 1ml | £535.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG1 Kappa
Antibody Clonality: Monoclonal
Antibody Clone: C6
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
EB11; NMDAR2D; NR2D; N-Methyl-d-Aspartate Receptor Subunit 2D; Glutamate [NMDA] receptor subunit epsilon-4
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
Glutamate Receptor, Ionotropic, N-Methyl-D-Aspartate 2D
Potency (Clone Number):
C6
Source:
Monoclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;
Immunocytochemistry: 5-20ug/mL;
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Glutamate Receptor, Ionotropic, N-Methyl-D-Aspartate 2D (GRIN2D) | RPE809Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||